Innovative treatment of Alzheimer's disease and related disorders - Concept for a somatic gene therapy
Moreover, in AD, we could provide direct evidence for the selective cell death of neurons which have replicated their DNA. This directly proofs the link between cell cycle activation and cell death in neurons of the adult human central nervous system (CNS) and identifies the molecular control of cell cycle activation as therapeutic target. With this project, we aim to further develop a therapeutic concept of neuroprotection to slow down or even prevent cell death by neuron-specific targeting of the cell cycle by somatic gene therapy. The approach will also be applicable to other neurodegenerative disorders and non-neuronal disorders with unscheduled cell-cycle activation, such as cancer or atherosclerosis.
Workgroup
Partners
-
Amarantus BioScience Holdings, Inc. (AMBS)
Funding/Patent
granted Patents: EP2620447 (B1); KR101378353 (B1); applied Patents: WO2010089122 (A3); AU2010211289 (A1); CA2751531 (A1); CN102356156 (A); US2012004277 (A1)